Cstone Pharmaceuticals Co. Ltd. presented preclinical data of CS-2009, a trispecific antibody targeting PD-1, CTLA-4 and VEGF-A, for cancer immunotherapy.
Researchers from Canwell Biotech Ltd. presented preclinical data for CAN-2109, a novel long-acting immunogenic cell death inducer being developed for the treatment of cancer.
The use of interleukin-2 (IL-2)-directed therapies has been associated with systemic toxicities, regulatory T cell (Treg) activation and limited efficacy so far. Researchers from Regeneron Pharmaceuticals Inc. have described REGN-10597 (PD1-IL2Ra-IL2), a programmed cell death protein 1 (PD-1)-targeted, receptor-masked IL-2 immunocytokine.
Astellas Pharma Inc. presented the first preclinical data on ASP-1002, a bispecific antibody targeting claudin-4 (CLDN4) and CD137, for the treatment of patients with metastatic or locally advanced solid tumors.
Researchers from Zymeworks Inc. recently reported preclinical data for ZW-220, an antibody-drug conjugate (ADC) consisting of humanized IgG1 monoclonal antibody targeting sodium-dependent phosphate transport protein 2B (SLC34A2, NaPi2b) conjugated to a topoisomerase I inhibitor, being developed for the treatment of cancer.
Antibody-drug conjugates (ADCs) combine monoclonal antibody-targeting capabilities with the cytotoxic effect of conjugated drug payloads. However, there is a need for enhanced strategies to overcome restricted therapeutic window or unacceptable off-target effects.
The University of Texas MD Anderson Cancer Center has launched its Institute for Cell Therapy Discovery & Innovation, which seeks to build upon MD Anderson clinical and research expertise to advance impactful cell therapies.
Evolveimmune Therapeutics Inc. has unveiled EVOLVE-205, a new 2:1 T-cell engager targeting CD20 with integrated affinity-tuned CD3 and CD2 agonists to promote anti-B-cell immunity.
At the Society for Immunotherapy of Cancer (SITC) meeting that ended yesterday in Houston, Dragonfly Therapeutics Inc. reported the first preclinical data on DF-6215, an alpha-active IL-2-Fc, for cancer immunotherapy.
RSS
